CAH Stock Analysis: Cardinal Health | NYSE
Medical Distribution | NYSE, USA | Market Cap: 64.288m USD | 12M Return: 39% | US14149Y1082 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 447M
EPS Trend: 97.3%
Qual. Beats: 5
Rev. Trend: 91.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Cardinal Health, Inc. (NYSE: CAH) is a U.S.-headquartered healthcare services and products company that operates two reportable segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. Founded in 1979 and based in Dublin, Ohio, the company distributes branded, generic, and specialty pharmaceuticals along with over-the-counter health and consumer products to hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and home-care patients.
In addition to pharmaceutical distribution, Cardinal Health manufactures and distributes its own branded medical, surgical, and laboratory products (gloves, needles, wound care, surgical drapes, and procedure kits), offers pharmacy management services, operates community health center pharmacies, and provides supply chain solutions to healthcare providers. The company also produces and delivers radiopharmaceuticals, a specialized niche within nuclear medicine distribution.
As one of the large-cap players in the GICS Health Care Distributors sub-industry, Cardinal Health operates in a sector dominated by a few major U.S. pharmaceutical wholesalers that compete on scale, logistics efficiency, and service breadth rather than on product pricing. Its dual focus on pharmaceutical distribution and medical product manufacturing provides diversification across both drug and medical supply chains.
- Opioid litigation settlements pressure earnings and free cash flow
- Pharmaceutical segment margins compressed by generic drug pricing competition
- Specialty Solutions revenue expands via oncology network acquisitions
| Net Income: 1.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.17 > 1.0 |
| NWC/Revenue: -2.07% < 20% (prev -0.74%; Δ -1.33% < -1%) |
| CFO/TA 0.09 > 3% & CFO 5.60b > Net Income 1.82b |
| Net Debt (3.55b) to EBITDA (3.58b): 0.99 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (233.0m) vs 12m ago -2.51% < -2% |
| Gross Margin: 3.90% > 18% (prev 3.66%; Δ 0.24% > 0.5%) |
| Asset Turnover: 449.2% > 50% (prev 424.3%; Δ 24.90% > 0%) |
| Interest Coverage Ratio: 7.64 > 6 (EBIT TTM 2.60b / Interest Expense TTM 341.0m) |
| A: -0.09 (Total Current Assets 41.0b - Total Current Liabilities 46.3b) / Total Assets 59.5b |
| B: 0.04 (Retained Earnings 2.44b / Total Assets 59.5b) |
| C: 0.05 (EBIT TTM 2.60b / Avg Total Assets 57.4b) |
| D: -0.05 (Book Value of Equity -3.02b / Total Liabilities 62.4b) |
| Altman-Z'' = -0.20 = B |
| DSRI: 0.96 (Receivables 14.5b/13.8b, Revenue 258b/234b) |
| GMI: 0.94 (GM 3.66% / 3.90%) |
| AQI: 1.04 (AQ_t 0.26 / AQ_t-1 0.25) |
| SGI: 1.10 (Revenue 258b / 234b) |
| TATA: -0.06 (NI 1.82b - CFO 5.60b) / TA 59.5b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of November 17, 2026, the stock is trading at USD 283.85 with a total of 1,426,954 shares traded. Over the past week, the price has changed by +3.49%, over one month by +11.73%, over three months by +20.73% and over the past year by +38.97%.
Current recommended Stop Loss: 275.40 (which is 3% or 1.3 ATR below the current price).
Cardinal Health has received a consensus analysts rating of 4.47. Therefore, it is recommended to buy CAH.
- StrongBuy: 11
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 294.9 | 3.9% |
P/E Trailing = 35.9819
P/E Forward = 21.4592
P/S = 0.2494
P/B = 16.0657
P/EG = 1.3164
Revenue TTM = 258b USD
EBIT TTM = 2.60b USD
EBITDA TTM = 3.58b USD
Long Term Debt = 6.93b USD (from longTermDebt, last quarter)
Short Term Debt = 1.89b USD (from shortTermDebt, last quarter)
Debt = 8.81b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.55b USD (calculated: Debt 8.81b - CCE 5.26b)
Enterprise Value = 67.8b USD (64.3b + Debt 8.81b - CCE 5.26b)
Interest Coverage Ratio = 7.64 (Ebit TTM 2.60b / Interest Expense TTM 341.0m)
EV/FCF = 13.84x (Enterprise Value 67.8b / FCF TTM 4.90b)
FCF Yield = 7.22% (FCF TTM 4.90b / Enterprise Value 67.8b)
FCF Margin = 1.90% (FCF TTM 4.90b / Revenue TTM 258b)
Net Margin = 0.71% (Net Income TTM 1.82b / Revenue TTM 258b)
Gross Margin = 3.90% ((Revenue TTM 258b - Cost of Revenue TTM 248b) / Revenue TTM)
Gross Margin QoQ = 3.85% (prev 4.30%)
Tobins Q-Ratio = 1.14 (Enterprise Value 67.8b / Total Assets 59.5b)
Interest Expense / Debt = 3.87% (Interest Expense 341.0m / Debt 8.81b)
Taxrate = 20.19% (457.0m / 2.26b)
NOPAT = 2.08b (EBIT 2.60b * (1 - 20.19%))
Current Ratio = 0.88 (Total Current Assets 41.0b / Total Current Liabilities 46.3b)
Debt / Equity = -2.91 (negative equity) (Debt 8.81b / totalStockholderEquity, last quarter -3.02b)
Debt / EBITDA = 0.99 (Net Debt 3.55b / EBITDA 3.58b)
Debt / FCF = 0.72 (Net Debt 3.55b / FCF TTM 4.90b)
Total Stockholder Equity = -2.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.17% (Net Income 1.82b / Total Assets 59.5b)
RoE = -62.56% (negative equity) (Net Income TTM 1.82b / Total Stockholder Equity -2.91b)
RoCE = 64.75% (EBIT 2.60b / Capital Employed (Equity -2.91b + L.T.Debt 6.93b))
RoIC = 21.13% (NOPAT 2.08b / Invested Capital 9.84b)
WACC = 4.95% (E(64.3b)/V(73.1b) * Re(5.20%) + D(8.81b)/V(73.1b) * Rd(3.87%) * (1-Tc(0.20)))
Discount Rate = 5.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.80 | Cagr: -2.21%
[DCF] Terminal Value 76.67% ; FCFF base≈4.72b ; Y1≈5.14b ; Y5≈6.39b
[DCF] Fair Price = 407.4 (EV 97.7b - Net Debt 3.55b = Equity 94.2b / Shares 231.1m; r=8.35% [WACC [floored]]; 5y FCF grow 10.09% → 2.50% )
EPS Correlation: 97.26 | EPS CAGR: 21.90% | SUE: 2.44 | # QB: 5
Revenue Correlation: 91.12 | Revenue CAGR: 6.53% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-12-31): EPS=3.13 | Chg30d=+0.13% | Revisions=+25% | Analysts=10
EPS next Quarter (2027-03-31): EPS=3.36 | Chg30d=+0.16% | Revisions=-22% | Analysts=10
EPS current Year (2027-06-30): EPS=13.00 | Chg30d=+3.44% | Revisions=+0% | GrowthEPS=+18.7% | GrowthRev=+4.7%
EPS next Year (2028-06-30): EPS=14.33 | Chg30d=+1.97% | Revisions=+29% | GrowthEPS=+10.3% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: +6% (up=7, down=6)